We next further suppressed the FAK/AKT signals in NSCLC cells by using FAK inhibitor Y15 and AKT inhibitor 3CAI to treat integrin αvβ3 positive A549/PC-9 cells. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.